This week learn more about CDC's strategies to reduce waterborne diseases; the US change to a trivalent influenza vaccine; new data for Merck's pneumococcal vaccine; and how PCR testing can influence a patient diagnosis and outcome.
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence
C difficile, Antimicrobials, and the Patients Most Affected
Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort
New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection
Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile
LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients